1-Star Stocks Poised to Plunge: Orexigen Therapeutics?
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Orexigen Therapeutics (NAS: OREX) has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Orexigen's business and see what CAPS investors are saying about the stock right now.
Orexigenfacts
Headquarters (founded) | La Jolla, Calif. (since 2002) |
Market Cap | $399.9 million |
Industry | Biotechnology |
Trailing-12-Month Revenue | $3.4 million |
Management | CEO Michael Narachi (since 2009) |
Return on Capital (average, past 3 years) | (51.4%) |
Cash/Debt | $138.6 million / $0 |
Competitors | Abbott Labs |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 24% of the 262 All-Star members who have rated Orexigen believe the stock will underperform the S&P 500 going forward.
Just yesterday, one of those bears, jed71, cautioned Fools about getting too excited over Orexigen's recent speculation-fueled surge:
Obesity drug still not approved yet. Run up based on expectations and approval received by a different company, Arena Pharma, for a similar obesity drug. It will not hold the run up, because, well, [Orexigen] never holds these run ups.
If you want market-thumping returns, you need to protect your portfolio from any undue risk. Luckily, we've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another small-cap growth play with big potential. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the newTrackPoisedToCAPS account.
The article 1-Star Stocks Poised to Plunge: Orexigen Therapeutics? originally appeared on Fool.com.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Fool owns shares of Abbott. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
